Aclarion (NASDAQ:ACON) Posts Earnings Results, Misses Expectations By $0.29 EPS

Aclarion (NASDAQ:ACON) posted its quarterly earnings data on Wednesday. The company reported ($2.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29), FiscalAI reports. Aclarion had a negative return on equity of 83.63% and a negative net margin of 11,238.59%.The company had revenue of $0.02 million for the quarter.

Aclarion Stock Performance

Aclarion stock traded down $0.25 during trading on Wednesday, hitting $6.89. The company’s stock had a trading volume of 14,874 shares, compared to its average volume of 109,231. The stock’s fifty day moving average is $7.84 and its 200 day moving average is $7.40. Aclarion has a 1-year low of $6.20 and a 1-year high of $3,499.51. The stock has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.01 and a beta of 1.42.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $11,758.50.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.